Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAIN Begins (Part 2): Infectious Disease Society and Start-Up Companies Push for More

This article was originally published in RPM Report

Executive Summary

The ink is barely dry on new antibiotic incentives in the GAIN Act, but the anti-infective development community is pushing for more. New ideas include “pull” incentives modeled on biodefense programs.

You may also be interested in...

Antibiotic Incentive Legislation: Can Reimbursement Horn In?

There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.

Regulatory Pathway for Achaogen Looks Better; Is It Aimed At Viable Commercial Market?

With the FDA bottleneck for new anti-infectives showing signs of improvement, the next concern is whether providers will pay high premiums for new anti-infectives and the related challenge of finding the right patients to make high-cost treatments make sense.

An Antibiotic Anniversary Celebration: Deal-Making and Investment Are Active In Formerly Moribund Field

A year ago, the Pew Trust hosted a meeting on antibiotic development that emphasized the many barriers still discouraging investment in the field despite new legislation (the GAIN Act). Three coincidental announcements in early 2014 show that the development freeze in anti-infectives is beginning to thaw.

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts